13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001907884
Total reported value
$1.8B
$1.8B
31 檔
25.4%
As reported in its official Q2 2025 Form 13F filing, Kynam Capital Management, LP's tracked investment portfolio stood at $1.8B with 31 total positions.
In Q2 2025, Kynam Capital Management, LP adopted a defensive or profit-taking posture, trimming 21 positions and completely liquidating 4 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CLDX | Celldex Therapeutics Inc | Stock-Other | 13.37% | -0.48% | -6.14% | |
| 2 | PCVX | Vaxcyte Inc | Stock-Other | 10.75% | -1.09% | -4.01% | |
| 3 | VERA | Vera Therapeutics Inc | Stock-Other | 8.69% | -1.58% | +42.79% | |
| 4 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 8.59% | -1.87% | — | |
| 5 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 8.16% | -1.95% | -5.21% | |
| 6 | CGON | Cg Oncology Inc | Stock-Other | 6.88% | — | -5.90% | |
| 7 | VRDN | Viridian Therapeutics Inc | Stock-Other | 6.66% | +3.72% | -5.79% | |
| 8 | COGT | Cogent Biosciences Inc | Stock-Other | 6.56% | -1.75% | -6.73% | |
| 9 | BEAM | Beam Therapeutics Inc | Stock-Other | 4.43% | -0.02% | -3.99% | |
| 10 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 3.30% | +0.76% | -42.42% | |
| 11 | WVE | Wave Life Sciences Ltd. | Stock-Other | 3.19% | -0.43% | EXIT | |
| 12 | TVTX | Travere Therapeutics Inc | Stock-Other | 2.45% | +1.84% | -14.54% | |
| 13 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.40% | — | -3.16% | |
| 14 | DVAX | Dynavax Technologies CORP | Stock-Other | 2.29% | — | -18.14% | |
| 15 | ✓ | Engene Holdings Inc | Stock-Other | 1.96% | -0.57% | EXIT | |
| 16 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 1.70% | +0.40% | -10.37% | |
| 17 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.44% | +0.46% | +46.70% | |
| 18 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.08% | +2.54% | -5.75% | |
| 19 | AMRN | Amarin CORP PLC -adr | Stock-Other | 1.01% | +0.05% | — | |
| 20 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.97% | +2.46% | +2526.29% | |
| 21 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.53% | +0.15% | — | |
| 22 | GERN | Geron CORP | Stock-Other | 0.52% | -0.15% | -5.55% | |
| 23 | IRWD | Ironwood Pharmaceuticals Inc | Stock-Other | 0.42% | — | -6.12% | |
| 24 | CRBU | Caribou Biosciences Inc | Stock-Other | 0.42% | -0.05% | -6.16% | |
| 25 | STRO | Sutro Biopharma, Inc. | Stock-Other | 0.39% | — | -6.49% | |
| 26 | DSGN | Design Therapeutics Inc | Stock-Other | 0.37% | -0.52% | EXIT | |
| 27 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.36% | — | -5.75% | |
| 28 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.36% | — | — | |
| 29 | BNR | Burning Rock Biotech Ltd-adr | Stock-Other | 0.34% | -0.64% | — | |
| 30 | LQDA | Liquidia CORP | Stock-Other | 0.27% | — | -68.44% | |
| 31 | CLYM | Climb Bio Inc | Stock-Other | 0.14% | -0.42% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VERA | Vera Therapeutics Inc | +3.9% | +42.79% | Add |
| 2 | CLDX | Celldex Therapeutics Inc | +3.5% | -6.14% | Trim |
| 3 | BCRX | Biocryst Pharmaceuticals Inc | +2.5% | -5.21% | Trim |
| 4 | COGT | Cogent Biosciences Inc | +2% | -6.73% | Trim |
| 5 | CGON | Cg Oncology Inc | +1.5% | -5.90% | Trim |
| 6 | VRDN | Viridian Therapeutics Inc | +1.3% | -5.79% | Trim |
| 7 | AMRN | Amarin CORP PLC -adr | +1% | NEW | New buy |
| 8 | URGN | UroGen Pharma Ltd. | +1% | +2526.29% | Add |
| 9 | NRIX | Nurix Therapeutics Inc | +0.6% | +46.70% | Add |
| 10 | PCVX | Vaxcyte Inc | +0.6% | -4.01% | Trim |
| 11 | CTMX | Cytomx Therapeutics Inc | +0.5% | NEW | New buy |
| 12 | TYRA | Tyra Biosciences Inc | +0.5% | -3.16% | Trim |
| 13 | RLAY | Relay Therapeutics Inc | +0.4% | -5.75% | Trim |
| 14 | EWTX | Edgewise Therapeutics Inc | +0.4% | NEW | New buy |
| 15 | BEAM | Beam Therapeutics Inc | +0.3% | -3.99% | Trim |
| 16 | CGEM | Cullinan Therapeutics Inc | +0.2% | -10.37% | Trim |
| 17 | CRBU | Caribou Biosciences Inc | +0.2% | -6.16% | Trim |
| 18 | ✓ | Proqr Therapeutics N.v. | +0.2% | -5.75% | Trim |
| 19 | STRO | Sutro Biopharma, Inc. | +0.1% | -6.49% | Trim |
| 20 | ✓ | Engene Holdings Inc | +0.1% | — | Unchanged |
| 21 | DSGN | Design Therapeutics Inc | +0.1% | +13.89% | Add |
| 22 | GERN | Geron CORP | 0% | -5.55% | Trim |
| 23 | CLYM | Climb Bio Inc | 0% | -1.78% | Trim |
| 24 | BNR | Burning Rock Biotech Ltd-adr | 0% | — | Unchanged |
| 25 | WVE | Wave Life Sciences Ltd. | -0.1% | -6.93% | Trim |
| 26 | SNDX | Syndax Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 27 | TVTX | Travere Therapeutics Inc | -0.3% | -14.54% | Trim |
| 28 | IRWD | Ironwood Pharmaceuticals Inc | -0.3% | -6.12% | Trim |
| 29 | ✓ | Amarin Corp PLC | -0.5% | EXIT | Sold out |
| 30 | LQDA | Liquidia CORP | -0.5% | -68.44% | Trim |
| 31 | DVAX | Dynavax Technologies CORP | -0.6% | -18.14% | Trim |
| 32 | IMCR | Immunocore Holdings Plc-adr | -0.9% | -42.42% | Trim |
| 33 | LEGN | Legend Biotech Corp-adr | -1.7% | EXIT | Sold out |
| 34 | SLNOEUR | Soleno Therapeutics Inc | -1.8% | EXIT | Sold out |
| 35 | NTRA | Natera Inc | -13.9% | EXIT | Sold out |
According to official SEC Form 13F filings, Kynam Capital Management, LP reported a total U.S. public equity portfolio value of $1.8B across 31 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CLDX, PCVX, VERA) accounted for 25.4% of total reported equity market value during Q2 2025.
Top New Position Initiated
AMRN
市值: $9.3M
Top Position Liquidated / Trimmed
NTRA
前期市值: $165.1M
During Q2 2025, Kynam Capital Management, LP's top holdings by market value included CLDX (13.4%)、PCVX (10.8%)、VERA (8.7%). The largest single position, CLDX, represented 13.4% of total portfolio value.
In Q2 2025, Kynam Capital Management, LP made 32 total portfolio adjustments, initiating 3 new buys, adding to 4 positions, trimming 21 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.